Biosimulation Market - Size, Share, trends,
and Forecast to 2026
Biosimulation plays important role in research and development process. Biosimulation is widely
used in consumer personalized medicine, owing to increasing demand for personalized medicine in
offering tailored solutions for various treatment areas such as drug discovery, oncology, cardiology,
infectious disease, and psychiatry. Predictive biosimulation offers effective platform to use
biological data and mathematical modeling to create a virtual version of patient to test simulated
treatments.
Moreover, continuous research is being conducted to create a low-priced or open source version of
predictive biosimulation platforms for self-tracking and modeling using patient’s data and to speed
up the adoption by software development communities to generate future health scenarios using
patient’s medication data.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/2016
Market Dynamics
Market players are engaged in developing novel biosimulation platform, in order to offer tailored
solution in each therapeutic area. This is expected to aid in growth of the market. For instance, in
October 2013, Rhenovia Pharma: a biotechnology firm specialized in biosimulation has developed
the first simulator for biological mechanism of epilepsy. Moreover, development of new simulator
opens new possibilities for research in epilepsy treatment. Rhenovia’ new simulator replicates the
basic biological mechanisms of signal transmission between brain cells and simulates its defects
leading to epileptic patterns, thereby leading to prevent epileptic seizures.
Furthermore, growing support from heathcare regulatory organizations in the adoption of
biosimulation based software and services will, augment future growth of biosimulation market.
Current FDA and EMA guidelines recommends the use of biosimulation in pediatric drug
development studies, thereby minimizing the impact on children that must enroll in clinical trials.
For instance, in Novembr 2017, Certara stated that U.S. Food and Drug Administration (FDA),
expanded its use of Certara’s PBPK Simcyp Population-based Simulator and its Pediatric and
Cardiac Safety Simulators. In addition, under the new agreement, FDA has tripled its number of